Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06891222 · ClinicalTrials.gov registry record
A Study of Electrocardiogram and Focused Cardiac Ultrasound for Enhanced Cardiac Disease Screening
A clinical trial of Cardiac Disease, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 10,500
- Enrollment target
- 1
- Study location
NCT06891222: Recruiting study of Cardiac Disease, sponsored by Mayo Clinic.
NCT06891222 is a study of Cardiac Disease that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 10,500 participants, above the 385-participant average among 24 other Cardiac Disease trials with a reported enrollment target (2627% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06891222, a study of Cardiac Disease, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 10,500 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate and compare the effectiveness of active screening for SHD in asymptomatic outpatients referred for an ECG, using a combination of AI-ECG and FOCUS. Invites will be sent and participants enrolled electronically.
Primary Outcome
Percentage of subjects to be diagnosed with SHD will be determined by the number of subjects that have a positive SHD screening. Positive SHD screening is defined by any one of the following: decreased LVEF (left ventricular ejection fraction), cardiac amyloidosis, aortic stenosis, and hypertrophic cardiomyopathy.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST AI-ECG (artificial intelligence-enabled electrocardiogram)
- DIAGNOSTIC_TEST Focus Screening (focused cardiac ultrasonography)
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,500 participants |
| Start Date | 2025-04-14 |
| Est. Completion | 2026-04 |
What NCT06891222 shows while recruiting
NCT06891222 is an observational study that tracks outcomes without assigning an intervention. Its 10,500 participants enrollment target places it among the larger protocols in the corpus, above the 385-participant average among 24 other Cardiac Disease trials with a reported enrollment target (2627% higher).
The record links to 1 condition, with Cardiac Disease appearing as the primary indexed condition, and to 2 interventions - of which AI-ECG (artificial intelligence-enabled electrocardiogram) is the first listed.
NCT06891222 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06891222 about?
NCT06891222 is a clinical study titled "A Study of Electrocardiogram and Focused Cardiac Ultrasound for Enhanced Cardiac Disease Screening". The purpose of this study is to evaluate and compare the effectiveness of active screening for SHD in asymptomatic outpatients referred for an ECG, using a combination of AI-ECG and FOCUS. Invites will be sent and participants enrolled electronically.
What is the current status of trial NCT06891222?
This trial is currently recruiting. The enrollment target is 10,500 participants. The study started on 2025-04-14. Estimated completion is 2026-04.
What conditions does trial NCT06891222 study?
This clinical trial studies the following conditions: Cardiac Disease.
What interventions are being tested in trial NCT06891222?
The interventions under investigation include: AI-ECG (artificial intelligence-enabled electrocardiogram) (DIAGNOSTIC_TEST), Focus Screening (focused cardiac ultrasonography) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06891222?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06891222 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiac Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06891222's enrollment target sits among peer trials
10,500 1st of 24 higher than 24 of 24 other Cardiac Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiac Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cardiac Performance System Data Collection Study - Minnesota
RECRUITING
-
Fresh Autologous Whole Blood Transfusion After Cardiopulmonary Bypass
RECRUITING · NA
-
Rectus Sheath Block in Cardiac Surgery
RECRUITING · NA
-
Opportunistic PK/PD Trial in Critically Ill Children (OPTIC)
RECRUITING
-
Factor VIII Inhibitor Bypass Activity (FEIBA) Versus Fresh Frozen Plasma As First Line Therapy For Bleeding After Cardiac Surgery
RECRUITING · Phase 2
-
The Effectiveness of 4D Image Acquisition and Post-processing With Vios Works
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05759299 · 10,500 participants
International obServational sTudy on AiRway manaGement in operAting Room and Non-operaTing Room anaEsthesia
- NCT07157774 · 10,450 participants · Phase 3
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
- NCT06081517 · 10,600 participants
Evaluating Disparities in Precision Oncology
- NCT06468202 · 10,742 participants · Phase 4
Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI